The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 08, 2017

Filed:

Oct. 17, 2014
Applicant:

Sunesis Pharmaceuticals, Inc., South San Francisco, CA (US);

Inventor:

Glenn Michelson, San Francisco, CA (US);

Assignee:

Sunesis Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4375 (2006.01); A61K 31/7068 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01); A61K 31/706 (2006.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4375 (2013.01); A61K 31/513 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A61K 38/18 (2013.01); A61K 38/19 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01);
Abstract

Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.


Find Patent Forward Citations

Loading…